{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T00:46:19Z","timestamp":1697935579435},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T00:00:00Z","timestamp":1343260800000},"content-version":"vor","delay-in-days":10709,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1983,4]]},"abstract":"<jats:p>1 Hexobarbitone plasma kinetics were determined in six healthy volunteers, who received 500 mg hexobarbitone orally. In addition urinary excretion rate and cumulative excretion were measured of its three major metabolites: 3\u2032\u2010hydroxyhexobarbitone, 3\u2032\u2010ketohexobarbitone and 1,5\u2010dimethylbarbituric acid. 2 The mean plasma elimination half\u2010 life of hexobarbitone was 3.7 +\/\u2010 0.9 h (n = 6). Assuming complete absorption, the volume of distribution and the metabolic clearance were 81.3 +\/\u2010 20.5 1 and 16.4 +\/\u2010 2.9 1\/h, respectively. The mean maximal plasma concentration was 7.1 +\/\u2010 2.1 micrograms\/ml and was reached 1.2 +\/\u2010 0.4 h after drug administration. 3 3\u2032\u2010Hydroxyhexobarbitone and 3\u2032\u2010 ketohexobarbitone, which are products of allylic side\u2010chain oxidation of hexobarbitone, were excreted in 24 h to the extent of 4.7 +\/\u2010 1.3 and 32.1 +\/\u2010 11.9% of the dose, respectively. In the same period, 1,5\u2010 dimethylbarbituric acid, which is the end product of the epoxide\u2010diol pathway, was excreted to 18.0 +\/\u2010 7.8% of the dose. The ratio of the sum of 3\u2032\u2010hydroxy\u2010 and 3\u2032\u2010ketohexobarbitone vs 1,5\u2010dimethylbarbituric acid excreted varied with time and amounted ultimately in 24 h urine to 2.3 +\/\u2010 1.0. 4 The half\u2010lives of 3\u2032\u2010hydroxyhexobarbitone and 1,5\u2010 dimethylbarbituric acid, calculated from their renal excretion rate curves, amounted 5.2 +\/\u2010 0.9 and 6.6 +\/\u2010 1.3 h and were significantly longer than the half\u2010life of hexobarbitone in plasma. The half\u2010life of 3\u2032\u2010ketohexobarbitone was 4.2 +\/\u2010 0.8 h. The maximum excretion rate of 1,5\u2010dimethylbarbituric acid was reached at 7.7 +\/\u2010 1.0 h after administration of hexobarbitone. 3\u2032\u2010Hydroxy\u2010 and 3\u2032\u2010ketohexobarbitone were excreted with a maximal rate at 2.2 +\/\u2010 0.8 and 2.8 +\/\u2010 0.4 h respectively.<\/jats:p>","DOI":"10.1111\/j.1365-2125.1983.tb01530.x","type":"journal-article","created":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T17:26:51Z","timestamp":1343323611000},"page":"459-464","source":"Crossref","is-referenced-by-count":7,"title":["Disposition of hexobarbitone in healthy man: kinetics of parent drug and metabolites following oral administration."],"prefix":"10.1111","volume":"15","author":[{"given":"NP","family":"Vermeulen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CT","family":"Rietveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DD","family":"Breimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,7,26]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/recl.19790980519"},{"key":"e_1_2_1_3_1","unstructured":"BREIMER D.D.(1974).Pharmacokinetics of hypnotic drugs.Ph.D.\u2010thesis Nijmegen The Netherlands."},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01066591"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(00)83147-7"},{"key":"e_1_2_1_6_1","article-title":"Assessment and prediction of in vivo oxidative drug metabolizing activity","author":"BREIMER D.D.","year":"1983","journal-title":"Pharmacokinetics. A Modern View"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1975184433"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/03602537208993914"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498257909042337"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1978.tb13191.x"},{"key":"e_1_2_1_11_1","first-page":"15","article-title":"The metabolic fate of hexobarbital in the rat","volume":"188","author":"HOLCOMB R.R.","year":"1974","journal-title":"J. Pharmac. exp. Ther."},{"key":"e_1_2_1_12_1","first-page":"33","article-title":"Increased gastro\u2010intestinal absorption of hexobarbital by hydrophilization","volume":"115","author":"LAGAS M.","year":"1980","journal-title":"Pharm. Weekblad Sci. Ed."},{"key":"e_1_2_1_13_1","first-page":"381","article-title":"Metabolismus von Hexobarbital bei Hepatitis and Cirrhosis. Z","volume":"15","author":"RICHTER E.","year":"1977","journal-title":"J. Gasteroenterologie"},{"key":"e_1_2_1_14_1","first-page":"249","article-title":"Alternative transport pathways of cholephilic hexobarbital metabolites in rats with experimental hepatitis and cholestasis","volume":"26","author":"RICHTER E.","year":"1979","journal-title":"Acta Hepatogasterol."},{"key":"e_1_2_1_15_1","first-page":"45","article-title":"Amobarbital metabolism in man: N\u2010glucoside formation","volume":"21","author":"TANG B.K.","year":"1978","journal-title":"Res. Comm. chem. Path. Pharmac."},{"key":"e_1_2_1_16_1","first-page":"315","article-title":"Metabolic fate of phenobarbital in man: N\u2010glucoside formation","volume":"7","author":"TANG B.K.","year":"1979","journal-title":"Drug. Metab. Disp."},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(78)90274-5"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498257909038732"},{"key":"e_1_2_1_19_1","article-title":"Disposition of hexobarbital in the rat; estimation of \u201cfirst\u2010pass\u201d elimination and influence of ether anaesthesia","author":"VERMEULEN N.P.E.","year":"1982","journal-title":"J. Pharmac. exp. Ther."},{"key":"e_1_2_1_20_1","first-page":"1422","article-title":"Zirkadiane Schwankungen pharmacokinetischer Parameter nach oraler Gabe von Hexobarbital","volume":"29","author":"ALTMAYER P.","year":"1979","journal-title":"Arzneim.-Forsch.\/Drug. Res."},{"key":"e_1_2_1_21_1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/cpt1978235525","article-title":"Hexobarbital disposition in compensated and decompensated cirrhosis of the liver","volume":"23","author":"ZILLY W.","year":"1979","journal-title":"Clin. Pharmac. Ther."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.1983.tb01530.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.1983.tb01530.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T07:30:14Z","timestamp":1697700614000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.1983.tb01530.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1983,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1983,4]]}},"alternative-id":["10.1111\/j.1365-2125.1983.tb01530.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.1983.tb01530.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1983,4]]}}}